Health Care & Life Sciences » Biotechnology | Caladrius Biosciences Inc.

Caladrius Biosciences Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
14,668.50
17,938.80
22,487.60
-
-
225
Cost of Goods Sold (COGS) incl. D&A
13,162.40
15,966.90
20,454.90
450.30
372.00
225
Gross Income
1,506.00
1,971.90
2,032.60
450.30
372.00
225
SG&A Expense
38,315.00
59,712.70
53,608.50
29,051.70
27,221.00
19,362
EBIT
36,809.00
57,740.80
51,575.80
-
27,593.00
19,587
Unusual Expense
1,822.00
3,080.00
44,013.30
-
-
-
Non Operating Income/Expense
207.10
154.00
536.40
23.90
273.10
3,424
Interest Expense
281.40
755.70
2,128.40
1,779.70
377.80
5
Pretax Income
38,705.20
55,570.40
98,254.00
31,257.80
27,697.70
16,168
Income Tax
780.10
104.20
17,243.50
-
11,526.60
-
Consolidated Net Income
39,485.30
55,466.20
81,010.50
31,257.80
16,171.10
16,168
Net Income
38,981.20
54,872.90
80,886.00
31,015.90
15,988.70
16,167
Net Income After Extraordinaries
38,981.20
54,872.90
80,886.00
29,375.60
54,956.10
16,167
Net Income Available to Common
38,981.20
54,872.90
80,886.00
32,656.30
28,765.30
16,167
EPS (Basic)
19.00
16.80
16.70
4.99
2.56
1.67
Basic Shares Outstanding
2,049.60
3,275.60
4,850.80
6,548.30
8,969.00
9,689
EPS (Diluted)
19.02
16.75
16.67
4.99
2.56
1.67
Diluted Shares Outstanding
2,049.60
3,275.60
4,850.80
6,548.30
8,969.00
9,689
EBITDA
35,203.30
55,553.80
48,889.10
29,051.70
27,221.00
19,362
Minority Interest Expense
504.10
593.30
124.50
241.80
182.50
1

About Caladrius Biosciences

View Profile
Address
110 Allen Road
Basking Ridge New Jersey 07920
United States
Employees -
Website http://www.caladrius.com
Updated 07/08/2019
Caladrius Biosciences, Inc. operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease. Its business includes the development of novel proprietary cell therapy products, as well as a revenue-generating contract development and manufacturing service business that it leverages for the development of therapeutics while providing service to other companies in the cell therapy industry developing products.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.